Saniona appoints Robert Hoffman to Board of Directors as Chair of the Audit Committee
September 16 2021 - 10:50AM
Saniona appoints Robert Hoffman to Board of Directors as Chair of
the Audit Committee
PRESS RELEASE
16 September
2021
Saniona (OMX: SANION), a clinical stage
biopharmaceutical company focused on rare diseases, today
announced the appointment of
Robert E. Hoffman to its board of
directors, as resolved at
the extraordinary shareholders’ meeting
held on September 16,
2021. Hoffman is an experienced
financial executive and board member with nearly 30 years of
experience and achievements in accounting, finance, fund raising,
strategic planning, corporate governance, investor relations, and
leadership.
“Robert’s depth of experience leading and advising U.S.-listed
companies on corporate finance, investor relations and related
activities will be valuable as we continue to develop our board and
evaluate a future U.S. listing,” said J. Donald deBethizy, Chairman
of the Saniona Board of Directors.
“I see in Saniona a company with a considerable amount of
untapped potential. There is incredible depth in the pipeline and
the talent, and I look forward to supporting and advising the team
on how to ensure Saniona’s potential is appreciated and valued,”
said Hoffman.
Hoffman currently sits on three publicly-traded company boards
with market capitalizations ranging from $30 million to $300
million (ASLAN Pharmaceuticals – Nasdaq: ASLN, Kintara Therapeutics
– Nasdaq: KTRA, and Antibe Therapeutics – TSX: ATE), serving as
chairman on one of the boards and as financial expert on the other
boards. Hoffman also serves as a board member of the Association of
Bioscience Financial Officers and FibroBiologics, Inc., a private
biotechnology company. In his most recent operating role, Hoffman
was Chief Financial Officer (CFO) of San Diego-based Heron
Pharmaceuticals, a Nasdaq-listed, commercial-stage drug developer
with a pipeline of acute pain therapeutics. During his tenure at
Heron, the company raised more than $650 million and launched its
second commercial drug product. Hoffman’s career in the
biotechnology sector began in 1997 at Arena Pharmaceuticals, where
he was a member of the founding management team and rose to become
CFO, holding that position for ten years. While at Arena, he was
involved in its Initial Public Offering (IPO) and financings,
raising more than $1.5 billion. Hoffman was the financial lead in
two Arena acquisitions, including a Swiss manufacturing facility,
and he became managing director of the facility upon the closing of
the transaction. Hoffman also was an advisor to the Financial
Accounting Standard Board (FASB) for 10 years (2010 to 2020),
advising the United States accounting rulemaking organizations on
emerging issues and new financial guidance. As a founder of Day For
Change, a not-for-profit that serves underprivileged and abused
children in San Diego, Hoffman has served on its board of directors
for 20 years. Hoffman received his BBA in accounting from St.
Bonaventure University and is a licensed CPA (Inactive) in the
State of California.
Hoffman is considered independent in relation to the company,
its senior management and major shareholders. Hoffman does not own
shares in Saniona.
For more information, please
contact Trista Morrison, Chief Communications Officer,
Saniona. Office: + 1 (781) 810-9227. Email:
trista.morrison@saniona.com
The information was submitted for publication, through the
agency of the contact person set out above, at 17.50 CEST on 16
September 2021.
About SanionaSaniona is a
clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing innovative therapies for patients
suffering from rare diseases for which there are a lack of
available treatment options. The company’s lead product candidate,
Tesomet, is in mid-stage clinical trials for hypothalamic obesity
and Prader-Willi syndrome, serious rare disorders characterized by
severe weight gain, disturbances of metabolic functions and
uncontrollable hunger. Saniona has developed a proprietary ion
channel drug discovery engine anchored by IONBASE™, a database of
more than 130,000 ion channel modulators, of which more than 20,000
are Saniona’s proprietary compounds. Through its ion channel
expertise, Saniona is advancing two wholly-owned ion channel
modulators, SAN711 and SAN903. SAN711 is in a Phase 1 clinical
trial and may be applicable in the treatment of rare neuropathic
disorders, and SAN903 is in preclinical development for rare
inflammatory, fibrotic and hematological disorders. Led by an
experienced scientific and operational team, Saniona has an
established research organization in the Copenhagen area, Denmark,
and a corporate office in the Boston, Massachusetts area, U.S. The
company’s shares are listed on Nasdaq Stockholm Small Cap (OMX:
SANION). Read more at http://www.saniona.com.
- BOD press release 09.16.21
Saniona Ab (LSE:0RQJ)
Historical Stock Chart
From Jan 2025 to Feb 2025
Saniona Ab (LSE:0RQJ)
Historical Stock Chart
From Feb 2024 to Feb 2025
